Other equities research analysts have also recently issued reports about the stock. Analysts at UBS AG (NYSE: UBS) reiterated a “neutral” rating on shares of Complete Genomics in a research note to investors on Tuesday. Separately, analysts at Mizuho cut their price target on shares of Complete Genomics from $10.00 to $6.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock.
Shares of Complete Genomics traded down 0.45% during mid-day trading on Tuesday, hitting $2.23. Complete Genomics has a 52 week low of $2.21 and a 52 week high of $18.55. The company’s market cap is $74.7 million.
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform.